Interim report
Page 1
INTERIM REPORT Q3 2025 NANOLOGICA AB (PUBL)
Page 2
FINANCIAL SUMMARY • Net sales for the third quarter amounted to SEK 2,843 thousand (611) and for the nine -month period to SEK 15,930 thousand (7,822) • Operating loss for the quarter amounted to SEK -10,017 thousand (-22,203) and for the nine-month period to SEK -30,021 thousand (-47,365) • Loss before tax for the quarter amounted to SEK -10,998 thousand (-23,701) and for the nine-month period to SEK -33,481 thousand (-51,561) • Earnings per share before and after dilution were SEK -0.12 (-0.54) for the quarter and SEK -0.38 (-1.24) for the nine-month period. • Cash and cash equivalents as of September 30, 2025 amounted to SEK 13,970 thousand (4,087) EVENTS DURING THE THIRD QUARTER • New equipment was commissioned in one process step, which resulted in increased yield and faster production in this process step. EVENTS AFTER THE END OF THE PERIOD • In October, Nanologica received its first order on the insulin market. The order amounted to appx. SEK 2 million and relates to the evaluation of the company's silica-based purification media NLAB Saga® on a production scale. The customer is a Chinese insulin manufacturer. • A supplementary order was received in October from a customer in the US for evaluation of NLAB Saga® on a production scale. The order value amounted to appx. SEK 2.7 million. • In October, Nanologica received an order for NLAB Saga® worth approximately SEK 1 million from a new distribution partner in China Interim Report Q3 2025 Nanologica AB (publ) 2 * Alternative performance measures that are not defined by IFRS. For definition, please see note 10. The quarter refers to April – June 2025. Amounts in brackets refer to comparative figures for the corresponding period of the previous year. Unless otherwise stated, this interim report refers to the group. This report in English is a translation of the original report in Swedish. In case of any discrepancies, the report in Swedish has precedence. Key Figures (group) 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Net sales (TSEK) 2 843 611 15 930 7 822 14 538 Operating profit/loss (TSEK) * -10 017 -22 203 -30 021 -47 365 -59 255 Profit/loss before income tax (TSEK) -10 998 -23 701 -33 481 -51 561 -65 594 Cash flow from operating activities (TSEK) -10 682 -23 474 -30 428 -56 139 -80 734 Cash and cash equivalents (TSEK) 13 970 4 087 13 970 4 087 48 430 Total equity (TSEK) 40 453 -8 838 40 453 -8 838 74 112 Average number of shares 88 369 820 44 178 618 88 365 415 41 501 126 49 533 602 Number of shares, end of period 88 369 820 44 178 618 88 369 820 44 178 618 88 357 234 Earnings per share (basic and diluted) (SEK) -0,12 -0,54 -0,38 -1,24 -1,32 Equity per share (SEK) * 0,46 -0,20 0,46 -0,20 0,84 Equity/asset ratio (%) * 40 -9 40 -9 52 Average number of employees 18 16 17 15 15 Number of employees, end of period 19 16 19 16 16
Page 3
With stable production and a first order on the insulin market, the company is advancing its positions, although this did not translate into significantly higher sales during the past quarter. Stable production gives us a more secure delivery capacity and thereby the conditions to create stronger customer relationships. This is beginning to be reflected in the order intake for the fourth quarter, which already amounts to approximately SEK 5.7 million. After several delays it is very satisfying that we finally established a stable production of NLAB Saga® during the quarter. The commissioning of new equipment to reach this point has been gratifyingly successful and resulted in both increased yield and faster lead time for the process step. Going forward , this will result in significantly higher production volumes. This marks the first time I can say that we not only have a production of silica for preparative chromatography that works, but that we also have a production that is stable. Having a stable productionmakes us a significantly better partner for our customers and over time this will increase our credibility as a reliable supplier. This is central because what we deliver is an input to a strictly regulated manufacturing industry, which the pharmaceutical industry is. In the beginning of the fourth quarter, we received our first order for evaluation of NLAB Saga® in production scale within insulin manufacturing, the market segment for which we initially developed our business in preparative chromatography before GLP-1 analogues became widely accepted as weight loss drugs. We therefore have a product variant that suits insulin manufacturers well, and we also have products in stock. The purpose of the evaluation is for the customer to use the product in their ongoing production. Since this can lower their manufacturing costs, they are prepared to change their process and have also obtained regulatory permits to do so. The order shows that we can sell both variants of our main product. Replacement of equipment in production was made during the spring and was scheduled to generate the first products by mid-year, which however was delayed until the beginning of September. This meant that during the quarter we did not have any amount of our most requested variant of NLAB Saga® to offer customers, with low sales as a result. Net sales in the third quarter were thus lower than we previously expected. For the third quarter, net sales amounted to SEK 2,843 thousand, which resulted in sales for the first nine months of the year of SEK 15,930 thousand. CEO COMMENT CEO Andreas Bhagwani Interim Report Q3 2025 Nanologica AB (publ) 3
Page 4
We delivered our first order to the US during the quarter, where NLAB Saga® will be evaluated on a production scale. The customer manufactures peptide drugs and the fact that our production now is stable allows us to complete this order already in the fourth quarter. The US market is important to us since the majority of all new peptide drugs are developed there. At the end of September, we launched NLAB® Idun, an ion exchange chromatography media that is a complement to NLAB Saga® in the purification of peptide-based drugs. We have customers who are evaluating the product, and we believe that this may provide a valuable revenue addition for the company in the long term. At the same time, it strengthens our brand in the chromatography market, where we can now offer our customers a complete workflow for the purification of peptide-based drugs. Nanologica is now entering a new phase. Our credibility with our customers increases significantly now that we have stable production. This means that we expect more and eventually also larger business. We have finally been able to start the work of optimizing production, which provides opportunities to achieve higher efficiency, both in terms of costs and volumes. Higher production volumes and subsequent sales in several markets mean that we can now for real set our sights on taking the company to profitability. Södertälje in October 2025 Andreas Bhagwani, CEO Interim Report Q3 2025 Nanologica AB (publ) 4
Page 5
Better and cheaper medicine to a larger number of patients Nanologica is a Swedish life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, we have developed an expertise in chromatography. This expertise combined with our high-quality products allows us to streamline our customers' workflows and lower their costs. Nanologica's products are used to purify pharmaceuticals during production through a technique called preparative chromatography. Our main product NLAB Saga®, a silica-based purification media for preparative chromatography, has been specially developed for the purification of peptide drugs such as insulin and GLP-1 analogues (e.g. Ozempic® and Wegovy®). A proprietary production method allows us to precisely control the shape, size, porosity and surface properties of silica particles, giving us the opportunity to create first-class products. Thanks to its efficient and long-lasting purification, NLAB Saga® can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for peptide drugs for the treatment of diabetes and obesity. Our mission is to increase the availability of cost-effective medicines through our purification products, thereby contributing to more patients worldwide having access to life-saving treatments for these diseases, at an affordable price. At the headquarters in Södertälje, Sweden, there is development of new products, customer support in the form of application support and method development, as well as small-scale production of silica. For large- scale production, the company works together with partners, where large-scale production of silica takes place at a manufacturer in the UK and Ireland in factories with multi-ton scale capacity. Nanologica's goal is to establish a growing, sustainable and profitable business in preparative chromatography in a global market. The company’s share (NICA) is listed on Nasdaq Stockholm's main market since 2022. For further information, please visit www.nanologica.com. THIS IS NANOLOGICA Interim Report Q3 2025 Nanologica AB (publ) 5
Page 6
Interim Report Q3 2025 Nanologica AB (publ) 6 FIVE REASONS TO INVEST IN NANOLOGICA By developing chromatography products that enable pharmaceutical manufacturers to streamline their production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients across the world having access to adequate treatments. Nanologica supplies advanced consumables to pharmaceutical manufacturers on a global and growing market for the purification of protein and peptide drugs, such as insulin and GLP-1 analogues. The market is insensitive to economic cycles, and the growth is driven by both an increased prevalence of diabetes and obesity, and the launch of new drugs for these diseases. 1 Fast-growing addressable market The market for high-quality silica for chromatography is an oligopoly market with a few producers, where only one produces the same type of high-quality silica as Nanologica. The growth of the underlying markets has resulted in a lack of supply capacity in the manufacture of high-quality silica. 2 Oligopoly market with capacity shortage Commercialization of the company’s products is expected to lead to a sharp increase in sales and Nanologica intends to build strong references through high product quality, reliable delivery times, and superior application support. By broadening the offering with complementary products and services to the same customer base, the addressable market will increase significantly, and customers will be tied closer to the company. 4 Ongoing commercialization and a clear growth strategy Nanologica's silica-based purification media is especially developed for insulin and peptide purification and has been successfully tested by several customers. The products purify effectively and last a long time, which means that they can increase productivity and lower production costs for pharmaceutical manufacturers. 3 High-quality products By providing products and services that contribute to lower costs and more efficient production for pharmaceutical manufacturers, Nanologica can enable more patients across the world access to life-saving medicines at affordable prices. 5 Enabling vital medicines for more patients
Page 7
OPERATING INCOME AND RESULT Net sales for the third quarter amounted to SEK 2,843 thousand (611), of which preparative chromatography amounted to SEK 2,658 thousand (10) and analytical chromatography amounted to SEK 185 thousand (263). During the quarter, the order for NLAB Saga® worth appx. SEK 1.3 million that was received in June has been delivered to the customer in the US. For the nine-month period, net sales amounted to SEK 15,930 thousand (7,822), of which SEK 14,605 thousand (6,891) is attributable to preparative chromatography and SEK 1,324 thousand (593) to analytical chromatography. Operating loss for the third quarter amounted to SEK -10,017 thousand (-22,203) and for the nine- month period to SEK -30,021 thousand (-47,365). During the quarter, the cost of raw materials and supplies increased compared to last year as a result of increased production, which was offset by a related positive change in product inventory. Net financial items amounted to SEK -981 thousand (-1,499) for the quarter and for the nine- month period to SEK -3,460 thousand (-4,196), mainly due to debt financing. Loss after tax for the quarter amounted to SEK -10,998 thousand (-23,701) and for the nine-month period to SEK -33,481 thousand (-51,596). Earnings per share before and after dilution for the quarter were SEK -0.12 (-0.54) and for the nine-month period SEK -0.38 (-1.24). INVESTMENTS, LIQUIDITY, AND FINANCIAL POSITION On September 30, the inventory amounted to SEK 30,696 thousand compared to SEK 32,745 thousand at the beginning of the year, of which the finished goods inventory corresponded to SEK 29,470 thousand compared to SEK 28,807 thousand at the beginning of the year. The finished goods inventory consists mainly of NLAB Saga® silica media of a type intended for insulin production, but partly also of the purification media NLAB® Siv. During the quarter, finished goods inventories increased as a result of production, while deliveries of goods from inventories were made against orders. Prepaid costs related to production amounted to SEK 30,862 thousand on the balance sheet date, compared to SEK 30,505 thousand at the beginning of the year. This refers to advances to Nanologica's manufacturers for ongoing production of silica. On September 30, capitalized development expenses amounted to SEK 12,334 thousand, compared to SEK 15,234 thousand at the beginning of the year. This mainly relates to the development of large-scale production of silica. Right-of-use assets amounted to SEK 5,529 thousand on the balance sheet date compared to SEK 11,212 thousand at the beginning of the year, which mainly refers to dedicated equipment for large-scale production of silica at the company's manufacturers. Cash flow for operating activities for the third quarter amounted to SEK -10,682 thousand (-23,473) and for the nine-month period to SEK -30,428 thousand (-56,139). Total cash flow for the quarter amounted to SEK -12,350 thousand (-10,776) and for the nine-month period to SEK -33,864 thousand (-5,545). Cash and cash equivalents amounted to SEK 13,970 thousand (4,087) on the balance sheet date. The group's reported equity amounted to SEK 40,453 thousand on the balance sheet date compared to SEK 74,112 thousand at the beginning of the year and the parent company's equity amounted to SEK 34,648 thousand compared to SEK 68,641 thousand at the beginning of the year. The board of directors notes that the company's liquidity and financial position are significantly affected by the timing and scope of both future sales and production costs and therefore monitors this continuously TAX The company pays taxes and fees in accordance with applicable legislation. As regards to tax on profit or loss, the company does currently not pay any tax due to negative earnings. As of December 31, 2024, the group had tax loss deductions amounting to SEK 349,745 and the parent Interim Report Q3 2025 Nanologica AB (publ) 7
Page 8
company had tax loss deduction amounting to SEK 349,985. The tax loss deductions may be activated when the requirements for activation of the deferred tax asset are met. The tax loss deductions are not time limited. FLUCTUATIONS IN REVENUE GENERATION The business generates revenue through the sale of products for preparative and analytical chromatography, and the provision of application development and other services. Sales of products for preparative chromatography are expected to account for the majority of the company's sales in 2025. Nanologica lacks significant seasonal variations. EMPLOYEES AND ORGANIZATION On September 30, 2025, the number of permanent employees was 19 (16), of which 14 (11) are women and 5 (5) are men. The number of consultants and project employees corresponds to 2 (4.5) full-time equivalents. THE SHARE AND SHAREHOLDERS Nanologica's share has been listed on Nasdaq Stockholm's main market since 2022, under the ticker NICA. The ISIN code is SE0005454873. As of June 30, 2025, the number of shares in the company amounted to 88,369,820 and the registered share capital amounted to SEK 4,506,860.82. The quota value per share was SEK 0.051. Mandatory bid from Flerie Invest AB On April 25, 2025, Flerie Invest AB announced that the company had acquired additional shares in Nanologica and that their holdings thereafter amounted to a total of 38,222,779 shares, corresponding to approximately 43.26 percent of the total number of shares and votes in Nanologica. Through the acquisition of additional shares, an obligation arose for Flerie Invest, according to the Takeover Rules, to make a public offer for the remaining shares in Nanologica within four weeks of the acquisition (a so-called mandatory bid). On May 23, 2025, Flerie announced a mandatory bid to the shareholders of Nanologica of SEK 1.00 per share. The acceptance period for the offer expired on 15 July and a total of 293,815 shares were tendered, corresponding to approximately 0.33 per cent of the number of shares and votes in the company. Flerie Invest AB subsequently held a total of 38,516,594 shares in Nanologica, corresponding to approximately 43.59 percent of the shares and votes in the company. Share-based incentive programs Warrant program 2023/2026 for management team and employees Each warrant of series TO 2023/2026 entitles the holder to subscribe for one new share in the company during the period 1 August 2026 to 30 November 2026 at a subscription price of SEK 30 per share. In the program, 180,000 of the total 245,000 warrants have been subscribed for. Based on the number of shares in the company as of the date of the report, the dilution effect will be a maximum of 0.2 percent if all options under the program are exercised. The incentive program does not entail any cost to the company. FINANCIAL CALENDAR Year-End Report 2025 February 12, 2026 Annual Report 2025 March 27, 2026 Interim Report Q1 2026 April 23, 2026 Financial reports will be published on Nanologica’s website at 08.10 on the announced date. Interim Report Q3 2025 Nanologica AB (publ) 8 Owners as of September 30, 2025 Shares Share % Flerie Invest AB 38,516,594 43.6 Konstakademien 4,258,218 4.8 Vega Bianca AB 4,034,528 4.6 Avanza Pension 2,933,564 3.3 Nordnet Pensionsförsäkring AB 1,846,084 2.1 Andre Oscar o Anna Wallenbergs stiftelse 1,835,281 2.1 CJ Hall Invest AB 1,784,746 2.0 Nowo Global Fund 1,479,426 1.7 Swedbank Robur Microcap 1,040,243 1.2 SEB AB Luxembourg Branch 895,256 1.0 The ten largest shareholders 58,623,940 66.4 Other shareholders (2,802) 29,745,880 33.6 Total 88,369,820 100.0
Page 9
FUTURE PROSPECTS This report contains forward-looking statements. Actual outcomes may differ from these statements. Internal and external factors can affect Nanologica's results. As the large-scale silica production facility delivers significantly larger volumes than before, larger product volumes have been delivered to customers with well-defined and market-based delivery times. This is expected to significantly facilitate the commercialization of NLAB Saga®. The company's opportunities to initiate substantially larger sales with continued sales growth in the coming years are therefore considered as good. RISKS AND UNCERTATINTIES The company makes assumptions, assessments and estimates that affect the content of the financial statements. Actual outcomes may differ from these assessments and estimates, as stated in the accounting principles. The goal of the group's risk management is to identify, prevent, measure, control and limit the risks in the business. Significant risks are the same for the parent company and the group. The risks in Nanologica's operations include strategic risks related to, among other things, the company's operations, industry, legal and regulatory risks, such as financing of upscaling projects, commercialization, research, trademarks, and external requirements, and operational risks such as production risks, price changes on raw materials and inputs, and currency fluctuations. A detailed description of risk exposure and risk management can be found in Nanologica's Annual Report for 2024 on pages 51–54. No significant changes in material risks or uncertainties occurred during the reporting period beyond what is described under the section "External factors". Interim Report Q3 2025 Nanologica AB (publ) 9 ANNUAL GENERAL MEETING The Annual General Meeting is planned to be held on May 21, 2026 in Stockholm. All AGM documents, including the Annual Report, will be available on the company's website no later than three weeks prior to the AGM. The documents will also be available at the company's head office. Nomination Committee The nomination committee for Nanologica AB's Annual General Meeting 2026 has been appointed in accordance with the current nomination committee instructions. The chairman of the board has contacted Nanologica's three largest shareholders or owner groups in terms of voting rights as of September 30, 2025, each of whom has been offered to appoint a representative to constitute the nomination committee of Nanologica AB for the 2026 Annual General Meeting. The nomination committee thus consists of the following three members: • Carl-Johan Spak (Flerie Invest AB) • Niklas Sjöblom (Konstakademiens stiftelser) • Kalle Olby (Vega Bianca AB) The nomination committee represents 53.0 percent of the voting rights of all voting shares in Nanologica AB as of September 30, 2025. The nomination committee's task is to present proposals for the 2026 Annual General Meeting regarding the election of the chairman of the meeting, the number of board members to be elected by the meeting, election of the chairman of the board and other members of the board, board fees and any remuneration for committee work, election of auditors (if applicable) and auditors' fees, as well as proposals for the principles that shall apply to the composition and work of the nomination committee for the next Annual General Meeting. Shareholders who wish to submit proposals to the nomination committee for the 2026 Annual General Meeting may do so by e-mail to valberedning@nanologica.com no later than January 31, 2026.
Page 10
EXTERNAL FACTORS The ongoing trade tensions between the US and other countries do not currently have a direct impact on the company's operations. The company's assessment is that any tariffs will have the same impact on all silica suppliers globally since none have production in the US. The company's current loans run at fixed interest rates, which means that the costs for these are not affected by higher interest rates during the term of the loans. Regarding fluctuations in exchange rates, the company's production and commitments are mainly in British pounds while sales are mainly in US dollars. Nanologica has not currently hedged any exchange rates. The company works continuously to identify, evaluate, and manage external factors that have an impact on its operations. AUDITORS REVIEW This interim report has been subject to review by the company’s auditors. The auditor’s report will be available on Nanologica’s website nanologica.com/corporate-governance-reports/. Interim Report Q3 2025 Nanologica AB (publ) 10 Gisela Sitbon Chairman of the board Mattias Bengtsson Board member Thomas Eldered Board member Anders Rabbe Board member Lena Torlegård Board member Andreas Bhagwani Chief Executive Officer ASSURANCE The board of directors and the CEO provide their assurance that this interim report provides a fair and true overview of the parent company’s and the group’s operations, financial position, and results, and describes material risks and uncertainties faced by the parent company and the companies in the group. October 22, 2025 For further information, please contact: CEO Andreas Bhagwani, andreas.bhagwani@nanologica.com CFO Eva Osterman, eva.osterman@nanologica.com
Page 11
FINANCIAL REPORTS AND NOTES
Page 12
Amounts in TSEK 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Net sales 2 843 611 15 930 7 822 14 538 Change in inventories, finished goods 5 886 -2 328 3 125 12 632 18 163 Other operating income -5 171 -106 228 633 Operating expenses Raw materials and consumables -8 264 -762 -15 277 -17 355 -28 408 Other external costs -3 062 -4 515 -10 011 -12 639 -17 127 Staff costs -5 444 -4 882 -17 494 -15 973 -21 555 Depreciation and impairment of tangible, intangible and right-of-use assets -2 045 -5 166 -8 868 -11 894 -15 548 Impairment of other current assets 0 -4 930 2 409 -9 005 -9 005 Reversal of provisions 0 0 0 0 592 Other operating expenses 74 -402 271 -1 181 -1 538 Total operating expenses -18 742 -20 656 -48 970 -68 047 -92 588 Operating profit/loss -10 017 -22 203 -30 021 -47 365 -59 255 Financial items Financial income -6 51 118 200 354 Financial costs -975 -1 550 -3 578 -4 396 -6 693 Total financial items -981 -1 499 -3 460 -4 196 -6 339 Profit/loss before income tax -10 998 -23 701 -33 481 -51 561 -65 594 Income tax 0 0 0 -35 -35 Profit/loss for the period attributable to owners of parent company -10 998 -23 701 -33 481 -51 596 -65 629 Other comprehensive income 0 0 0 0 0 Total comprehensive profit/loss for the period attributable to owners of parent company -10 998 -23 701 -33 481 -51 596 -65 629 Earnings per share (basic and diluted), SEK -0,12 -0,54 -0,38 -1,24 -1,32 Average number of ordinary shares during the period 88 369 820 44 178 618 88 365 415 41 501 126 49 533 602 Ordinary shares outstanding at the closing date 88 369 820 44 178 618 88 369 820 44 178 618 88 357 234 CONSOLIDATED INCOME STATEMENT Interim Report Q3 2025 Nanologica AB (publ) 12 Earnings per share for Jan-Sep 2024 have been adjusted as the average number of shares for the period has been recalculated after the then ongoing issue ended.
Page 13
EQUITY AND LIABILITIES Equity Share capital including ongoing issues 4 507 4 418 8 836 Additional paid-in capital 442 053 348 898 442 173 Profit/loss brought forward from actual period -406 107 -362 153 -376 896 Total equity attributable to parent company shareholders 40 453 -8 838 74 112 TOTAL EQUITY 40 453 -8 838 74 112 Long-term liabilities Lease liabilities 251 533 258 Provisions 0 583 0 Other long-term liabilities 28 583 24 24 Total long-term liabilities 28 834 1 140 282 Current liabilities Advance payment from customers 0 241 0 Accounts payable 7 613 14 069 13 103 Lease liabilities 172 3 454 2 896 Current loan liabilities 19 292 0 47 788 Other liabilities 692 76 492 956 Accrued expenses and deferred income 4 196 8 561 3 963 Total current liabilities 31 964 102 817 68 705 Total liabilities 60 798 103 956 68 987 TOTAL EQUITY AND LIABILITIES 101 251 95 119 143 099 Amounts in TSEK 2025 Sep 30 2024 Sep 30 2024 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 12 334 16 855 15 234 Concessions, patents, licenses, trademarks and similar rights 0 0 0 Tangible fixed assets 3 634 3 385 3 187 Right-of-use assets 5 529 13 048 11 212 Total fixed assets 21 497 33 287 29 633 Current assets Inventories 30 696 19 353 32 745 Accounts receivable 3 093 500 896 Other receivables 235 618 500 Prepaid expenses and accrued income 31 760 37 274 30 894 Cash and cash equivalents 13 970 4 087 48 430 Total current assets 79 754 61 832 113 466 TOTAL ASSETS 101 251 95 119 143 099 CONSOLIDATED BALANCE SHEET Interim Report Q3 2025 Nanologica AB (publ) 13
Page 14
Amounts in TSEK 2025 Jul - Sep 2024 Jul - Sep 2025 Jul - Sep 2024 Jan - Sep 2024 Jan - Dec Total equity at the beginning of the period 51 594 14 455 74 112 -1 898 -1 898 0 Profit/loss for the period -10 998 -23 701 -33 481 -51 596 -65 629 Other comprehensive income 0 0 0 0 0 Total comprehensive income for the period -10 998 -23 701 -33 481 -51 596 -65 629 Off set loans 0 0 0 6 176 22 125 Rights issue 0 0 38 48 043 131 496 Transaction costs -62 -1 453 -157 -10 318 -12 026 Group adjustments -82 1 862 -58 50 Total transactions with shareholders -144 409 -177 44 657 141 639 Total equity at the end of the period 40 453 -8 837 40 453 -8 837 74 112 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY Interim Report Q3 2025 Nanologica AB (publ) 14
Page 15
Amounts in TSEK 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Operating activities Operating profit/loss -10 017 -22 203 -30 021 -47 365 -59 255 Adjustment for items not affecting cash flow 1 956 5 163 8 689 11 706 15 359 Valuation of other current assets 0 4 930 -2 409 9 005 9 005 Reversal of provisions 0 0 0 0 -583 Interest received 52 51 156 200 354 Interest paid -975 -1 341 -3 021 -3 946 -6 280 Cash flow from operating activities before changes in working capital -8 984 -13 399 -26 605 -30 401 -41 400 Cash flow from changes in working capital Increase (-) / decrease (+) of inventories -2 007 2 978 2 049 -16 380 -29 771 Increase (-) / decrease (+) of operating receivables -779 -8 523 -389 -17 775 -12 376 Increase (+) / decrease (-) of operating liabilities 1 089 -4 530 -5 484 8 417 2 812 Cash flow from operating activities -10 682 -23 474 -30 428 -56 139 -80 734 Investing activities Investments in intangible assets 0 -37 0 -480 -480 Investments in tangible fixed assets -872 -8 -872 -262 -262 Losses when liquidating subsidiary 0 0 0 0 0 Investments in right-of-use assets 0 0 0 0 0 Compensation for sold tangible fixed assets 0 0 0 0 0 Compensation for divested financial assets 0 0 0 0 0 Cash flow from investing activities -872 -45 -872 -742 -742 Financing activities Rights issue for the year 0 0 38 48 043 131 496 Premiums for issued/repurchased warrants 0 0 0 -6 -6 Adjustment of share capital 0 0 0 0 0 Transaction costs -62 -1 453 -157 -10 317 -12 026 New loans 0 15 000 0 15 000 15 000 Amortization of lease liabilities -744 -808 -2 494 -1 374 -2 216 Amortization of financial loans 9 3 48 -11 -12 020 Cash flow from financing activities -796 12 742 -2 564 51 335 120 228 Total cash flow for actual period -12 350 -10 776 -33 864 -5 545 38 752 Cash and cash equivalents, opening balance 26 378 15 076 48 430 10 054 10 054 Exchange rate difference in cash and cash equivalents -58 -212 -596 -421 -376 Cash and cash equivalents, closing balance 13 970 4 087 13 970 4 087 48 430 CONSOLIDATED CASH FLOW STATEMENT Interim Report Q3 2025 Nanologica AB (publ) 15 Changes have been made to the reporting for the period Jan - Sep 2024 to clarify transaction costs in connection with share issues.
Page 16
NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664- 5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is Forskargatan 20 G, 151 36 Södertälje, Sweden. The main operation of the group is production and sales of chromatography products. Nanologica AB has four subsidiaries; Nanghavi AB, Nanologica Black AB, Nanologica Yellow AB and Nlab Bioscience S.A. Nlab Bioscience S.A is under liquidation. The other subsidiaries are dormant at the time of the publication of the report. The interim report for Q3 2025 has been approved for publishing on October 23, 2025in accordance with a board decision on October 22, 2025. NOTE 2 ACCOUNTING PRINCIPLES The consolidated financial statements for Nanologica AB (publ) have been prepared in accordance with IFRS (International Financial Reporting Standards) as adopted by the EU, the Annual Accounts Act and the Swedish Financial Reporting Board’s RFR 1 Supplementary Accounting Rules for Groups. The parent company’s financial statements are presented in accordance with the Swedish Annual Accounts Act and RFR 2 Accounting for Legal Entities. This interim report is presented in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. Disclosures in accordance with IAS 34 are presented both in notes and elsewhere in interim report. The accounting principles and calculation methods applied are in accordance with those described in the Annual Report 2024. The guidelines of the European Securities and Markets Authority (ESMA) on alternative performance measures have been applied. This involves disclosure requirements for financial measures that are not defined by IFRS. For performance measures not defined by IFRS, see note 10 Definition of key figures. Information for the quarter refers to the second quarter of 2025 unless otherwise stated. Amounts expressed in SEK thousand and SEK million refer to thousands of Swedish kronor and millions of Swedish kronor, respectively. Amounts in brackets refer to comparative figures for the previous year. NOTE 3 SIGNIFICANT ACCOUNTING ASSESSMENTS AND ASSUMPTIONS Important estimates and assessments are described in detail in Nanologica's Annual Report 2024 on pages 73–75. During the first quarter, the impairment of current assets made in Q3 2024 was reassessed and resulted in a reversal of parts of the impairment. During the first half of the year, the company conducted a review of the inventory, which resulted in adjusted inventory values and disposal of obsolete material. No other significant changes in assessments and assumptions have been noted for the reporting period. This report includes statements that are forward-looking, and actual results may differ from those stated. NOTE 4 DISTRIBUTION OF INCOME Nanologica's distribution of revenues from the sales of goods broken down by type of revenue, geographic market, and larger customers. All sales of goods have taken place at a certain time. The provision of services such as application development has been recognized as revenue over time when the services have been performed. NOTES Interim Report Q3 2025 Nanologica AB (publ) 16
Page 17
Composition of net sales, per product type (TSEK) 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - dec Preparative chromatography 2 658 10 14 605 6 891 12 727 Analytical chromatography 185 263 1 324 593 808 Application development and similar services 0 338 0 338 1 003 Total 2 843 611 15 930 7 822 14 538 NOTE 5 INVENTORIES Interim Report Q3 2025 Nanologica AB (publ) 17 NOTE 6 INFORMTATION ON FINANCIAL ASSETS AND LIABILITIES For assets and liabilities that are reported at amortized cost, the company assesses that the carrying value of its receivables and liabilities corresponds to fair value. This assessment is based, inter alia, on the discount effect, which is considered to be insignificant in view of the maturity of the claims and liabilities and the prevailing market conditions. Since the company's receivables and liabilities mainly have a short maturity, the difference between carrying amount and fair value is considered to be negligible. Composition of net sales, per region (TSEK) 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Chromatography 2 843 611 15 930 7 822 14 538 China 1 360 121 13 708 2 478 8 426 India 33 380 117 5 176 5 916 USA 1 450 0 1 458 21 21 Europe 0 0 0 0 Rest of the World 0 110 620 148 175 Total 2 843 611 15 930 7 822 14 538 Composition of net sales, large customers (TSEK) 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Customer A - Chromatography 1 300 0 10 739 0 0 Customer A (%) 46% 0% 67% 0% 0% Customer C - Chromatography 0 0 467 4 715 4 715 Customer C (%) 0% 0% 3% 60% 32% Customer C - Chromatography 0 0 0 86 137 Customer C (%) 0% 0% 0% 1% 1% Customer D - Chromatography 26 42 485 2 147 7 911 Customer D (%) 1% 7% 3% 27% 54% Others - Chromatography 1 517 569 4 239 874 1 775 Others (%) 53% 93% 27% 11% 12% Total 2 843 611 15 930 7 822 14 538 Amounts in TSEK 2025 Sep 30 2024 Sep 30 2024 Dec 31 Raw materials 0 131 131 Semi-finished products and production in progress 1 225 645 3 807 Finished products 29 470 18 577 28 807 Total 30 696 19 353 32 745
Page 18
Amounts in TSEK, group 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Jun 2024 Jan - Sep 2024 Jan - Dec Depreciations 2 045 3 737 8 868 10 466 14 119 Write-downs/disposals of intangible assets 0 1 426 0 1 426 1 426 Write-downs/disposals of fixed assets -90 3 -90 3 3 Other items 0 -3 -89 -189 -189 Total 1 956 5 163 8 689 11 705 15 359 NOTE 7 ITEMS NOT AFFECTING CASH FLOW NOTE 8 RELATED PARTY TRANSACTIONS Transactions with Flerie AB regarding loans. Flerie AB is Nanologica's largest owner. Thomas Eldered is part- owner and chairman of the board of Flerie AB, as well as a board member of Nanologica AB. Information regarding loans Loans from Flerie Invest AB have been raised on market terms during the first half of 2022. The annual interest rate for the loans is 8 percent and interest on the loans is paid quarterly. On the balance sheet date, the outstanding loan amounted to approximately SEK 47.8 million. The end date of the loan has been extended to July 2, 2027 from July 5, 2025. Transactions during the third quarter Costs for loans from Flerie AB amounted to SEK 967 thousand during the quarter and refer to costs for interest and commitment fees. . NOTE 9 EVENTS AFTER THE END OF THE QUARTER • In October, Nanologica received its first order on the insulin market. The order amounted to appx. SEK 2 million and relates to the evaluation of the company's silica-based purification media NLAB Saga® on a production scale. The customer is a Chinese insulin manufacturer. • A supplementary order was received in October from a customer in the US for evaluation of NLAB Saga® on a production scale. The order value amounted to appx. SEK 2.7 million. • In October, Nanologica received an order for NLAB Saga® worth approximately SEK 1 million from a new distribution partner in China. Interim Report Q3 2025 Nanologica AB (publ) 18 Amounts in TSEK, parent company 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Depreciations 1 409 2 981 6 634 9 094 11 955 Write-downs/disposals of intangible assets 0 1 426 0 1 425 1 425 Write-downs/disposals of fixed assets -90 3 -90 3 3 Write-downs/disposals of other assets 0 -3 -89 -11 -11 Total 1 319 4 407 6 455 10 511 13 372
Page 19
NOTE 10 DEFINITION OF ALTERNATIVE PERFORMANCE MEASURES The company presents certain financial measures that are not defined under IFRS. These alternative performance measures are used in internal reporting and as part of management's follow-up of the group's results and financial position. The company believes that these measures provide valuable supplementary information to investors and the company's management, as they enable evaluation and benchmarking of the company's performance. Since not all companies calculate financial measures in the same way, these are not always comparable to measures used by other companies. These financial measures should therefore not be seen as a substitute for measures defined under IFRS. Reported key figures are defined according to IFRS unless otherwise stated. ESMA's guidelines on alternative performance measures are applied, which means disclosure requirements for financial measures that are not defined according to IFRS. Definitions of alternative performance measures Operating profit/loss (EBIT) Profit/loss before net financial items and taxes. (Earnings Before Interest and Taxes). Operating margin, %* Operating profit/loss in relation to net sales. In cases where the margin is negative, the margin is only reported as "neg”. Earnings before interest, tax, depreciation, and amortization (EBITDA)* In the quarterly data, the performance measure EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is used. EBITDA is calculated as operating profit/loss with the reversal of depreciation and amortization of intangible and tangible assets and right-of-use assets. Equity per share* Equity divided by the number of shares outstanding at the end of the period. Cash flow from operating activities per share* Cash flow from operating activities in relation to average number of shares before dilution. Equity/assets ratio* Equity in relation to the balance sheet total. Average number of shares during the period Calculated as an average of the number of ordinary shares outstanding during the reporting period on a daily basis. * Derivation of alternative performance measures Interim Report Q3 2025 Nanologica AB (publ) 19 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec A. Operating profit/loss (TSEK) -10 017 -22 203 -30 021 -47 365 -59 255 B. Net sales (TSEK) 2 843 611 15 930 7 822 14 538 A/B = Operating profit/loss (%) neg neg neg neg neg A. Operating profit/loss (TSEK) -10 017 -22 203 -30 021 -47 365 -59 255 B. Depreciation and amortization of tangible, intangible and right-of-use assets (TSEK) -2 045 -5 166 -8 868 -11 894 -15 548 A-B = Earnings before interest, taxes, depreciation and amortization (EBITDA), (TSEK) -7 972 -17 037 -21 153 -35 471 -42 235
Page 20
GROUP QUARTERLY DATA * Alternative performance measures that are not defined by IFRS. For definition, please see note 10. Interim Report Q3 2025 Nanologica AB (publ) 20 * In case of a negative result, no recalculation for dilution will be made. 2025 Sep 30 2024 Sep 30 2024 Dec 31 A. Equity according to the balance sheet (TSEK) 40 453 -8 838 74 112 B. Total assets according to balance sheet (TSEK) 101 251 95 119 143 099 A/B = Equity/assets ratio (%) 40 -9 52 0 A. Equity according to the balance sheet (TSEK) 40 453 -8 838 74 112 B. Number of shares before and after dilution* 88 369 820 44 178 618 88 357 234 A/B*1000 = Equity per share (SEK) 0,46 0 0,84 0 A. Cashflow from operating activities (TSEK) -10 682 -23 474 -80 734 B. Average number of shares before dilution during the period* 88 369 820 44 178 618 49 533 602 A/B*1 000 = Cashflow from operating activities per share (SEK) -0,12 -0,53 -1,63 Amounts in TSEK unless otherwise stated 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 Statement of comprehensive income Net sales 2 843 2 335 10 751 6 715 611 2 174 5 037 75 Total operating expenses -18 742 -13 740 -16 488 -24 541 -20 656 -24 938 -22 453 -38 265 Operating profit before depreciation and amortization (EBITDA)* -7 972 -7 583 -5 598 -8 236 -17 037 -6 757 -11 677 -26 906 Operating profit/loss (EBIT)* -10 017 -10 763 -9 241 -11 890 -22 203 -9 832 -15 331 -35 638 Operating margin,%* neg neg neg neg neg neg neg neg Total financial investments -981 -1 549 -930 -2 144 -1 499 -1 294 -1 403 -1 200 Profit/loss before income tax -10 998 -12 312 -10 171 -14 033 -23 701 -11 126 -16 734 -36 839 Total comprehensive profit/loss for the period attributable to -10 998 -12 312 -10 171 -14 033 -23 701 -11 126 -16 769 -36 839 owners of parent company Consolidated financial position Total fixed assets 21 497 23 231 25 991 29 633 33 287 34 801 37 862 38 899 Total current assets 65 784 63 000 70 748 65 036 57 745 56 341 46 463 28 476 Cash and cash equivalents 13 970 26 378 28 348 48 430 4 087 15 076 23 600 10 054 Total equity 40 453 51 594 63 940 74 112 -8 838 14 455 11 075 -1 898 Total long-term liabilities 28 834 43 132 42 899 282 1 140 61 365 61 239 67 465 Total current liabilities 31 964 17 882 18 248 68 705 102 817 30 399 35 610 11 863 Consolidated statement of cash flow Cash flow from operating activities -10 682 -552 -19 194 -24 595 -23 474 -23 919 -8 746 -5 568 Cash flow from investing activities -872 0 0 0 -45 -211 -486 -6 381 Cash flow from financing activities -796 -907 -862 68 893 12 742 15 766 22 827 -599 Total cash flow for actual period -12 350 -1 459 -20 056 44 297 -10 776 -8 364 13 595 -12 548 Other Key Figures Equity/assets ratio, %* 40 46 51 52 -9 14 10 -2 Number of employees at the end of the period 19 18 16 16 16 15 16 16 Average number of employees during the period 18 16 15 15 15 14 15 15 Average number of employees and consultants during the period 20 18 19 19 19 18 18 18 Data per share Earnings per share before and after dilution, SEK -0,12 -0,14 -0,14 -0,19 -0,54 -0,25 -0,46 -1,02 Equity per share (before dilution), SEK* 0,46 0,58 0,72 0,84 -0,20 0,33 0,31 -0,05 Cash flow from operating activities per share, SEK* -0,12 -0,01 -0,26 -0,33 -0,53 -0,54 -0,24 -0,15 Share price at the end of the period, SEK 1,15 1,16 1,30 1,82 2,24 5,76 6,76 10,40 Number of shares before dilution on average during the period 88 369 820 88 361 010 73 631 029 73 631 029 44 178 618 44 178 618 36 146 142 36 146 142 Number of shares before dilution at the end of the period 88 369 820 88 369 820 88 357 234 88 357 234 44 178 618 44 178 618 36 146 142 36 146 142 Number of warrants at the end of the period 180 000 180 000 180 000 180 000 180 000 980 000 980 000 980 000
Page 21
Amounts in TSEK 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Net sales 2 843 611 15 930 7 822 14 538 Change in inventories, finished goods 5 886 -2 328 3 125 12 632 18 163 Other operating income -5 171 -106 228 633 Operating expenses Raw materials and consumables -8 264 -762 -15 277 -17 355 -28 408 Other external costs -3 834 -5 405 -12 669 -14 391 -19 804 Staff costs -5 444 -4 882 -17 494 -15 973 -21 555 Depreciation and amortization of tangible, intangible and right-of-use assets -1 409 -4 410 -6 634 -10 522 -13 384 Impairment of other current assets 0 -4 930 2 409 -9 005 -9 005 Reversal of provisions 0 0 0 0 592 Other operating expenses 49 -402 241 -1 181 -1 538 Total operating expenses -18 902 -20 790 -49 425 -68 427 -93 101 Operating profit/loss -10 177 -22 336 -30 475 -47 745 -59 768 Financial items Exchange rate differences 0 -209 -538 -427 -391 Interest income and similar profit/loss items -6 51 118 200 354 Interest expense and similar profit/loss items -967 -1 303 -2 979 -3 910 -6 203 Profit/loss from financial items -973 -1 461 -3 399 -4 137 -6 240 Profit/loss before income tax -11 149 -23 798 -33 875 -51 882 -66 008 Income tax 0 0 0 0 0 Profit/loss for the period -11 149 -23 798 -33 875 -51 882 -66 008 INCOME STATEMENT FOR THE PARENT COMPANY STATEMENT OF COMREHENSIVE INCOME FOR THE PARENT COMPANY Interim Report Q3 2025 Nanologica AB (publ) 21 Amounts in TSEK 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Profit/loss for the period -11 149 -23 798 -33 875 -51 882 -66 008 Other comprehensive income Items that may be reclassified to result for the year 0 0 0 0 0 Comprehensive income for the period -11 149 -23 798 -33 875 -51 882 -66 008
Page 22
BALANCE SHEET FOR THE PARENT COMPANY Interim Report Q3 2025 Nanologica AB (publ) 22 Amounts in TSEK 2025 Sep 30 2024 Sep 30 2024 Dec 31 ASSETS Fixed assets Intangible assets Capitalized expenditure for research and development and similar 10 612 19 306 16 642 Total intangible assets 10 612 19 306 16 642 Tangible assets Equipment, tools and installations 3 634 3 385 3 187 Financial assets Participations in group companies 100 100 100 Total fixed assets 14 346 22 791 19 929 Current assets Inventories Inventories 30 696 19 353 32 745 Current receivables Accounts receivable 3 093 500 896 Other receivables 317 618 500 Prepaid expenses and accrued income 32 779 37 850 32 128 Total current receivables 36 189 38 968 33 524 Cash and cash equivalents Cash and cash equivalents 13 793 3 908 48 252 Total current assets 80 678 62 229 114 521 TOTAL ASSETS 95 024 85 019 134 450
Page 23
Amounts in TSEK 2025 Sep 30 2024 Sep 30 2024 Dec 31 EQUITY AND LIABILITIES Equity Share capital 4 507 4 418 8 836 Fund for development expenditure 55 375 281 Total restricted equity 4 562 4 792 9 117 Non-restricted equity Share premium reserve 442 053 348 898 442 173 Profit/loss brought forward -378 093 -316 734 -316 641 Profit/loss for the period -33 875 -51 882 -66 008 Total non-restricted equity 30 086 -19 718 59 524 Total equity 34 648 -14 926 68 641 Provisions Other provisions 0 583 0 Long-term liabilities Other long-term liabilities 28 583 0 0 Total long-term liabilities 28 583 0 0 Current liabilities Advanced payment from customers 0 241 0 Accounts payable 7 613 14 069 13 103 Current loan liabilities 19 292 76 492 47 788 Other liabilities 692 0 956 Accrued expenses and deferred income 4 196 8 561 3 963 Total current liabilities 31 793 99 363 65 809 Total liabilities 60 376 99 945 65 809 TOTAL EQUITY AND LIABILITIES 95 024 85 019 134 450 BALANCE SHEET FOR THE PARENT COMPANY Interim Report Q3 2025 Nanologica AB (publ) 23
Page 24
Amounts in TSEK 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Total equity at the beginning of the period 45 859 10 325 68 641 -6 940 -6 940 Share capital 0 -10 403 1 -10 403 -10 403 Non registered share capital 0 10 403 0 0 0 Reduction of share capital through rights issue 0 0 0 -3 294 -3 294 Share premium reserve 0 0 -1 0 0 Profit or loss brought forward 0 0 0 13 697 13 697 Total comprehensive income for the period -11 149 -23 798 -33 875 -51 882 -66 008 Off set loans through rights issue 0 0 0 6 176 22 125 Rights issue 0 0 38 48 043 131 496 Premiums for issued / repurchased warrants 0 0 0 -6 -6 Transaction cost -62 -1 453 -157 -10 317 -12 026 Total equity at the end of the period 34 648 -14 926 34 648 1 297 68 641 STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY Interim Report Q2 2025 Nanologica AB (publ) 24
Page 25
Amounts in TSEK 2025 Jul - Sep 2024 Jul - Sep 2025 Jan - Sep 2024 Jan - Sep 2024 Jan - Dec Operating activities Operating profit/loss -10 177 -22 336 -30 475 -47 745 -59 768 Adjustment for items not affecting cash flow 1 319 4 407 6 455 10 511 13 372 Write-down of onerous contract 0 4 930 -2 409 9 005 9 005 Reversal of provision 0 0 0 0 -583 Interest received 52 51 156 200 354 Interest paid -967 -1 303 -2 960 -3 888 -6 180 Income taxes received/paid 0 0 0 0 0 Cash flow from operating activities before changes in working capital -9 773 -14 252 -29 232 -31 917 -43 800 Cash flow from changes in working capital Increase (-) / decrease (+) of inventories -2 007 2 978 2 049 -16 380 -29 771 Increase (-) / decrease (+) of operating receivables -735 -8 479 -256 -21 717 -16 274 Increase (+) / decrease (-) of operating liabilities 1 089 -4 530 -5 482 12 492 6 888 Cash flow from operating activities -11 426 -24 282 -32 921 -57 522 -82 957 Investing activities Investments in intangible assets 0 -37 0 -480 -480 Investments in tangible assets -872 -8 -872 -262 -262 Cash flow from investing activities -872 -45 -872 -742 -742 Financing activities Rights issue for the year 0 0 38 48 043 131 496 Premiums for issued/repurchased warrants 0 0 0 -6 -6 Transaction cost -62 -1 453 -157 -10 317 -12 026 New loans 0 15 000 0 15 000 15 000 Amortization of financial loans 9 3 48 -11 -12 020 Cash flow from financing activities -52 13 550 -71 52 709 122 444 Total cash flow for actual period -12 350 -10 777 -33 863 -5 554 38 745 Cash and cash equivalents, opening balance 26 201 14 897 48 252 9 878 9 878 Exchange rate difference in cash and cash equivalents -58 -212 -596 -416 -371 Cash and cash equivalents, closing balance 13 793 3 908 13 793 3 908 48 252 CASH FLOW STATEMENT FOR THE PARENT COMPANY Interim Report Q2 2025 Nanologica AB (publ) 25 Changes have been made to the reporting for the period Jan - Sep 2024 to clarify transaction costs in connection with share issues.
Page 26
Nanologica AB (publ) Forskargatan 20 G SE-151 36 Södertälje, Sweden Ph: +46-8-410 749 49 www.nanologica.com